Utomilumab Biosimilar - Research Grade

Lee, K. Y., et al. Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment. Theranostics, 2026, 16(1), 17-36. 23

Human

4-1BB

>1mg/ml

Human IgG2-Lambda 2

Anti-Mouse 4-1BB (3H3) In Vivo Antibody - Low Endotoxin (ICH1036), Anti-Mouse 4-1BB (LOB12.3) In Vivo Antibody - Low Endotoxin (ICH1274), Urelumab Biosimilar - Research Grade (ICH5015), Evunzekibart Biosimilar - Research Grade (ICH5236), Exlinkibart Biosimilar - Research Grade (ICH5541)

https://www.imgt.org/mAb-DB/

ICH3002

Q07011

3604

RRID:AB_2921563

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of utomilumab, supplied for research use only. Utomilumab is a fully human IgG2 monoclonal antibody that binds the co-stimulatory receptor 4-1BB (CD137, TNFRSF9) and acts as an agonist to enhance T-cell and NK-cell activation. This research-grade analog is built around the same target and is intended as a tool reagent, not as the clinical drug; it is not for human or veterinary use. Presented in an unconjugated format, it is well suited to in-vitro binding and receptor-engagement studies, as a positive or benchmarking control alongside other anti-4-1BB agents, in ADCC/agonism assay development, and in preclinical model work exploring co-stimulatory pathways. It is offered as low-endotoxin material (research grade less than 1 EU/mg, with an ultra-low option less than 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support screening, assay standardization, and scale-up. Lot-to-lot handling should follow standard recombinant antibody storage and reconstitution practice. 4-1BB (CD137, encoded by TNFRSF9; UniProt Q07011) is a member of the tumor necrosis factor receptor superfamily and functions as an inducible co-stimulatory receptor. It is expressed mainly on activated CD8+ and CD4+ T cells, activated NK cells, regulatory T cells, and some myeloid and dendritic cells. Its natural ligand, 4-1BBL (CD137L, TNFSF9), is found on antigen-presenting cells. Ligand or agonist engagement drives receptor trimerization and higher-order clustering, recruiting TRAF1 and TRAF2 and activating NF-kappaB and MAPK signaling. This delivers a co-stimulatory signal that promotes T-cell proliferation, survival, cytokine production, and cytotoxicity, and enhances mitochondrial activity in CD8+ T cells. Because 4-1BB amplifies antitumor and antiviral immune responses, it is a prominent target for agonist immunotherapeutics.

4-1BB ligand receptor, T-cell antigen 4-1BB, Tnfrsf9, Ila, Ly63, CD137

Detects human CD137. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Utomilumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Utomilumab (anti-4-1BB) Biosimilar

Q: Is the Utomilumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Utomilumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Utomilumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Utomilumab that binds human 4-1BB.